OncLive On Air

We traveled to Tampa, Florida, for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from the faculty from Moffitt Cancer Center and Mayo Clinic.

We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from Dana-Farber Cancer Institute.

We traveled to Dallas, Texas, for a State of the Science Summit™ on Breast Cancer, where faculty relayed the prognostic value of genomic assays in breast cancer and the scope of established and ensuing treatment approaches for those with early-stage and advanced disease.

We recently traveled to Charlotte, North Carolina, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured expert insight on treatment approaches across metastatic colorectal cancer, locally advanced and metastatic pancreatic cancer, advanced hepatocellular carcinoma, neuroendocrine tumors, and advanced gastric cancer.

We traveled to New York City, New York, for a State of the Science Summit™ on Ovarian Cancer, where faculty shared their insight on the various surgical and medical treatment modalities in advanced ovarian cancer, as well as investigational interventions that may further define standards of care.

We traveled to Durham, North Caroline, for a State of the Science Summit™ on Gastrointestinal Malignancies, where faculty shared key updates from the 2019 Gastrointestinal Symposium.

We traveled to Chicago, Illinois, for a State of the Science Summit™ on Breast Cancer, where faculty provided a comprehensive look into present and potentially future standards of care in early-stage and advanced breast cancer subtypes.

We traveled to Washington, D.C., for a State of the Science Summit™ on Gastrointestinal Cancer, which focused on the clinically diverse and steadily expanding therapeutic armamentariums for patients with gastrointestinal malignancies.

We traveled to Kansas City, Missouri, for a State of the Science Summit™ on Hematologic Malignancies, which provided a comprehensive snapshot of the pivotal data that were presented at the 2018 ASH Annual Meeting.

Mario M. Leitao Jr, MD, FACOG, FACS, and Dmitriy Zamarin, MD, PhD, of Memorial Sloan Kettering Cancer Center, to discuss two common clinical scenarios faced in practice, and the data to support their approaches.